Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Trial Profile

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Feb 2018 According to a Mesoblast media release,this trial is being funded by the United States National Institutes of Health and the Canadian Institute of Health Research.
    • 21 Dec 2017 According to a Mesoblast media release, primary endpoint will be reached in Q1 2018.
    • 14 Sep 2017 Planned End Date changed from 1 Jan 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top